KGR 1380
Latest Information Update: 12 Oct 2006
At a glance
- Originator Kissei Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Diabetic complications in Japan (unspecified route)
- 26 May 2001 Profile reviewed but no significant changes made
- 03 Aug 1998 No-Development-Reported for Diabetic complications in Japan (Unknown route)